The Front Line Covid-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.

• The I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 can be downloaded here (PDF)
• A concise summary of the longer scientific review manuscript below can be downloaded here (PDF, continuously updated)
• Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol can be downloaded here (PDF, continuously updated)
• An introductory video further explaining the rationale by Dr. Pierre Kory can be found here (Vimeo)
• Paul Marik’s recent lecture on I-MASK+ is found here (YouTube)
• A video of an invited Grand Rounds Lecture on invermectin by Pierre Kory can be found here

In March, 2020 we first published our MATH+ Treatment Protocol for Covid-19, intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.